Chapters

Transcript

Video

What can you tell us about some of the key features of the CAHtalyst pediatric trial, including retention of trial subjects, and achieving androstenedione end points in patients on crinecerfont?

What can you tell us about some of the key features of the CAHtalyst pediatric trial, including retention of trial subjects, and achieving androstenedione end points in patients on crinecerfont?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Phyllis W. Speiser, MD

Phyllis W. Speiser, MD

Associate Professor, Institute of Molecular Medicine
Feinstein Institutes for Medical Research
Emerita Professor, Pediatrics Donald and Barbara Zucker School of Medicine
Hofstra/Northwell
New Hyde Park, NY